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Essential metals, such as iron and copper, play a critical role in a plethora of cellular 
processes including cell growth and proliferation. However, concomitantly, excess of these 
metal ions in the body can have deleterious effects due to their ability to generate cytotoxic 
reactive oxygen species (ROS). Thus, the human body has evolved a very well-orchestrated 
metabolic system that keeps tight control on the levels of these metal ions. Considering their 
very high proliferation rate, cancer cells require a high abundance of these metal compared to 
their normal counterparts. Interestingly, new anti-cancer agents have been developed that 
take advantage of the sensitivity of cancer cells to metal sequestration and their susceptibility 
to ROS. These ligands can avidly bind metals ions to form redox active metal complexes, 
which lead to generation of cytotoxic ROS. Furthermore, these agents also act as potent 
metastasis suppressors due to their ability to up-regulate the metastasis suppressor gene, N-
myc downstream regulated gene 1. This review discusses the importance of iron and copper 
in the metabolism and progression of cancer, how they can be exploited to target tumors and 








The essential transition metals, iron and copper, play an integral role in many important 
biological functions [1-3]. By acting as a co-factor within active sites, these metals are an 
essential component required for the activity of many proteins and enzymes that are vital for 
normal growth and development [2, 4]. For instance, both iron and copper are involved in 
oxidative phosphorylation, making them essential elements for energy generation [2, 3]. 
Additionally, iron is also required for the rate-limiting step of DNA synthesis that is 
catalyzed by ribonucleotide reductase (RR) [5-7]. Copper plays an important role in the 
detoxification of reactive oxygen species (ROS) via superoxide dismutase (SOD) and in the 
cross-linking of elastin and collagen [3, 8]. Moreover, copper is also a co-factor essential for 
the formation of new blood vessels, a process termed angiogenesis [9]. 
 
The utility of both iron and copper as co-factors originates from their ability to redox cycle 
[2, 3]. However, this same property that allows for the gain or loss of electrons also results in 
their cytotoxicity through the donation of electrons to oxygen, leading the generation of ROS, 
such as superoxide (O2
•-
) and hydroxyl radicals (
•
OH) [2, 10, 11]. Notably, ROS react rapidly 
with biological molecules, such as proteins, lipids and DNA [11, 12]. As a consequence, 
mammalian cells have evolved homeostatic mechanisms to tightly regulate the concentration 
of redox active metals, allowing their bioavailability for use, but at the same time preventing 
ROS generation [13-15]. 
 
Notably, the dyshomeostasis of iron and copper and the altered expression of proteins 
involved in their metabolism are often observed in malignancies [16, 17]. Evidence from 
epidemiological, clinical and experimental studies also suggests a link between altered iron 
and copper levels and the development of neoplasia [18-20]. This dysregulation of metal 
homeostasis reveals the potential vulnerability of cancer cells to therapeutic metal chelation. 
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In fact, the targeting of transition metals, such as iron and copper, has become an attractive 
strategy in the development of anti-cancer agents due to the higher requirement of neoplastic 
cells for these essential metals [2, 21]. 
 
In this review, developments in the physiological metabolism of iron and copper will be 
discussed and their roles in the progression of cancer and metastasis will be examined. 
Finally, the burgeoning field of targeting transition metals, such as iron and copper, as a 
novel anti-cancer strategy will be considered. 
 
2. Physiological Iron Metabolism 
2.1 Systemic Iron 
Iron is vital for mammalian cell survival, with cellular iron-depletion causing cell death by 
apoptosis [22, 23]. Adult humans contain 3-5 grams of iron, more than four fifths of which is 
found in hemoglobin within erythrocytes, while a further one fifth is stored within 
mononuclear phagocytes, also known as reticuloendothelial macrophages (e.g., splenic 
macrophages and hepatic Küpffer cells) and hepatocytes [24, 25]. Cellular iron storage 
typically occurs within the intracellular iron storage protein, ferritin [26]. The majority of the 
remaining iron is found within other heme-containing proteins (e.g., cytochromes), iron-
sulfur cluster (ISC)-containing proteins (e.g., succinate dehydrogenase of the mitochondrial 
respiratory chain) [13, 27, 28] and non-heme/non-ISC iron-containing proteins (e.g., iron- 
and 2-oxoglutarate-dependent dioxygenases) [29, 30]. Critically, ~20 mg of iron is required 
daily for the synthesis of new hemoglobin, with at least 90% of this iron being recycled on a 
daily basis from the turnover of old and damaged erythrocytes by splenic macrophages. 
Approximately 1-2 mg of iron is absorbed in the proximal duodenum to replace iron losses 
from bleeding, epithelial desquamation, sweating and urinary excretion [25]. 
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2.2 Iron Absorption 
Although there is no regulated pathway for systemic iron excretion, dietary iron absorption is 
very tightly regulated [31, 32]. Iron absorption occurs mainly in the duodenum (and upper 
jejunum), and this is increased by iron deficiency and decreased by systemic iron loading [25, 
33]. Iron is absorbed across the apical membrane of duodenal epithelial enterocytes of the 
mid and upper villus (Figure 1). These cells can absorb dietary iron, which is present in two 
major forms: non-heme iron, which abundant in most foods and is the major form of iron in 
cereals and vegetables; and heme iron, which is predominantly derived from hemoproteins 
(e.g., hemoglobin and myoglobin) in meat (for comprehensive reviews, see Sharp [34] and 
Gulec et al. [32]; Figure 1).  
 
2.2.1 Absorption of Heme Iron 
Notably, the absorption of heme is more efficient than non-heme iron, but the mechanisms 
remain poorly understood. Heme uptake is known to involve receptor-mediated endocytosis, 
but the mediators of this process are not known [35, 36]. Heme-carrier protein 1 (HCP1) was 
identified as a possible low affinity heme transporter, but subsequent studies showed it to act 
as a high affinity folate transporter (proton-coupled folate transporter (PCFT); Figure 1) [35, 
37, 38]. However, there is no convincing evidence that it plays a physiologically important 
role in heme transport [38]. Once inside enterocytes, heme is broken down into biliverdin and 
Fe(II) by heme oxygenase (HO), likely HO-1 (Figure 1) [39]. The regulation of intestinal 
heme iron uptake has recently been reviewed [32]. 
 
2.2.2 Absorption of Non-Heme Iron 
The uptake of dietary non-heme iron, which is typically in the form of low-Mr chelates of 
Fe(III), occurs in two phases. First, iron is taken up across the apical membrane of duodenal 
enterocytes, which requires soluble iron in its reduced form [40]. The reduction of non-heme 
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iron is thought to be mediated by an apical membrane ferrireductase. A candidate for such a 
reductase is duodenal cytochrome b561 (DCYTB/CYBRD1/CYB561A2; Figure 1) [41], 
although other reductases may play a more significant role. DCYTB is a di-heme 
transmembrane oxidoreductase that utilizes intracellular ascorbate as an electron donor to 
reduce extracellular Fe(III) [42]. An NAD(P)H-dependent transmembrane oxidoreductase, 
six transmembrane epithelial antigen of the prostate 2 (STEAP2) is also expressed in the 
apical membrane of duodenal enterocytes and may be involved in reduction of non-heme iron 
prior to uptake [43]. Importantly, non-heme iron can also be reduced by endogenous and 
secreted reductants [40], such as ascorbate [44-46]. 
 
Ferrous iron is then imported across the enterocyte’s apical membrane via the ferrous iron 
transporter, divalent metal transporter 1 (DMT1/SLC11A2; Figure 1) [47]. Other divalent 
metal transporters, such as the putative zinc transporter, ZRT/IRT-like protein 14 
(ZIP14/SLC39A14), may also be involved in iron transport [48]. 
 
2.3 Systemic Iron Transport  
Iron that has been imported by enterocytes can be exported to the circulation across the 
basolateral membrane by ferroportin 1 (FPN1/SLC40A1; Figure 1) [49, 50]. The trans-
plasma membrane copper-dependent ferroxidase and ceruloplasmin homologue, hephaestin, 
associates with FPN1 in the basolateral membrane and, in combination with copper-
dependent plasma ceruloplasmin, catalyzes the oxidation of exported Fe(II) to Fe(III) (Figure 
1) [51, 52]. During this process, two atoms of Fe(III) are complexed to the major plasma iron 
transport protein, transferrin (Tf), for transport and uptake by distal tissues (Figure 2). 
Importantly, Tf-bound iron is virtually the sole source of iron for the erythroid compartment 
leading to the daily production of 200 billion erythrocytes [24]. 
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2.4 Cellular Iron Uptake 
Under normal physiological conditions, most non-dietary iron is internalized by the uptake of 
Tf-bound iron (Figure 2). The Tf-bound iron is internalized by receptor-mediated endocytosis 
following its binding to Tf receptor 1 (TfR1; Figure 2) [53, 54]. Ferric iron is released from 
Tf within the endosome after its acidification and is then reduced by an endosomal 
ferrireductase, STEAP3 (Figure 2) [43, 54], or by a novel mechanism involving cellular 
ascorbate-dependent endosomal reduction [55-57]. Similarly to non-heme iron uptake by 
duodenal enterocytes, this ferrireduction is followed by transport of Fe(II) across the 
endosomal membrane by DMT1 (Figure 2) [58] or ZIP14 [59]. This newly acquired cytosolic 
iron then becomes part of a poorly-characterized “labile iron pool” (LIP) and can be utilized 
for metabolism, stored within the iron-storage protein, ferritin, or released back to the 
extracellular space (Figure 2) [53, 54]. Although TfR1-mediated endocytosis is the major 
pathway of iron uptake, other processes may be involved, these include: (1) a second Tf 
receptor (TfR2) [60] and (2) a quantitatively important second mechanism of iron uptake 
from Tf that is distinct from that mediated via TfR1 and which occurs by a process consistent 
with fluid phase endocytosis [61-64]. 
 
Although the uptake of Tf-Fe prevails under normal conditions, in diseases of iron overload 
(e.g., hereditary hemochromatosis and β-thalassemia), Tf becomes saturated with iron [53, 
65]. Under these conditions, iron that is in excess of Tf-iron-binding capacity occurs as low-
Mr iron chelates (e.g., ferric citrate) [24, 66]. These low-Mr complexes of iron and citrate are 
rapidly and markedly internalized by hepatocytes [67] and other cell-types [68] and are 
thought to play a major role in the pathogenesis of iron overload disease [53]. The uptake of 
this form of iron requires an initial ferrireduction event, which may involve one or more cell 
surface ferrireductases (e.g., DCYTB [42] or STEAPs 2-4 [69]). More recently, it has been 
shown that the release of cellular ascorbate may contribute to the reduction of at least 50% of 
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non-Tf-bound iron prior to uptake [45, 46, 55]. As above, the Fe(II) that is formed is 
imported by divalent metal transporters, such as DMT1 [58], ZIP14 or ZIP8 [59]. 
 
2.5 Intracellular Iron Trafficking 
Upon release from the endosome, iron is thought to enter the LIP (Figure 2) [70, 71]. The LIP 
is a poorly-characterized compartment believed originally to be comprised of iron complexed 
with low molecular-weight ligands, including citrate, ATP, other inorganic ions, proteins and 
sugars [70]. A recent study has suggested that Fe(II)-glutathione is a major component of this 
pool [72]. However, this proposal is not supported by studies using the GSH synthesis 
inhibitor, buthionine sulfoximine, which demonstrated no alteration in the ability of chelators 
to bind intracellular labile iron pools and induce efflux from cells [73]. Moreover, studies 
assessing the presence of a labile iron pool in reticulocytes demonstrated that there was no 
significant low-Mr pool and suggested that the iron was transported directly from protein to 
protein [74, 75], in analogy with intracellular copper trafficking [76, 77]. 
 
Direct organelle-organelle interactions may also be involved in iron transport, where Tf-
loaded endosomes transfer iron to the mitochondria through a “kiss-and-run” mechanism 
[75]. However, the precise molecular mechanisms involved remain unclear. More recently, 
the human poly (rC)-binding proteins (PCBPs) 1-4 have been proposed to act as chaperones 
to facilitate the delivery of iron to ferritin for storage [78, 79]. In addition, PCBPs 1 and 2 
appear to mediate iron acquisition by several members of a class of iron- and 2-oxoglutarate 
(2-OG)-dependent dioxygenases, which form a large family of non-heme iron enzymes that 
depend on the insertion of a single iron atom into their active site [29]. 
 
From the enigmatic LIP, iron is distributed to specific compartments within the cell. For 
instance, within erythroid precursors iron is directly targeted to mitochondria for heme 
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synthesis in a manner that appears to bypass the LIP [74, 80, 81]. In non-erythroid cells, iron 
derived from Tf-dependent iron uptake is either: (i) utilized by downstream metabolic 
pathways (e.g., imported into mitochondria for usage in ISC and heme synthesis, and/or 
incorporated in cytoplasmic iron-containing proteins); (ii) released from the cell by FPN1; 
and/or (iii) stored in ferritin (Figure 2). 
 
2.6 Intracellular Iron Storage: Ferritin 
In nucleated cells, most nascent imported iron is incorporated into ferritin (Figure 2) [26]. 
Ferritin is a multimeric protein composed of 24 subunits that forms a hollow sphere capable 
of storing ~4,500 iron atoms as a mineralized ferric, phosphate and hydroxide core [26, 82, 
83]. In mammals, cytosolic ferritin is composed of two different subunits: H-ferritin (heavy 
subunit, encoded by FTH1) and L-ferritin (light subunit, encoded by FTL), which form 
hetero-polymers of differing subunit compositions with tissue specific distributions [26, 82, 
83]. As Fe(II) enters a ferritin “nano-cage” it is oxidized to Fe(III) by the ferroxidase activity 
of H-ferritin in an oxygen-dependent manner [26, 82, 83]. Subsequently, iron(III) is then 
transported to the protein cavity, where core formation commences at the carboxyl or 
glutamate groups of L-ferritin, which are devoid of ferroxidase activity [26, 82, 83]. This 
enclosure and sequestration of iron as ferrihydrite prevents the occurrence of cytotoxic redox 
reactions [26, 82, 83]. 
 
Intracellular ferritin in the cytoplasm can be used as a source of bioavailable iron following 
their targeted autolysosomal proteolysis [84]. Lysosomal proteolysis is the primary 
degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for 
iron exit [85], although proteasomal degradation may occur under specific conditions [12, 
26]. The targeting of ferritin for autophagic turnover (i.e., ferritinophagy) involves nuclear 
receptor coactivator 4 (NCOA4), which binds to ATG8 proteins during the formation of 
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autophagosomes and recruits ferritin as a cargo molecule [86]. Considering that 
autophagocytosed macromolecules and organelles, such as ferritin and mitochondria, contain 
high iron levels, active lysosomal compartments are rich in iron [87]. 
 
Apart from cytosolic ferritin, a unique mitochondrial ferritin of the H-type has also been 
characterized that is found exclusively within the mitochondrion [88, 89]. It is encoded by an 
intronless gene on chromosome 5q23.1, which, once transcribed, leads to a subunit with a Mr 
of 22,000 Da that forms ferritin shells that may sequester potentially toxic iron [89]. 
Mitochondrial ferritin is highly expressed in the testis, but there are only low levels in iron 
storage organs. The role of mitochondrial ferritin remains unclear, although its expression 
markedly increases in sideroblastic anemia where heme synthesis is disturbed and 
mitochondrial iron-loading occurs [90]. Considering this, over-expression of mitochondrial 
ferritin in cellular models leads to mitochondrial iron-loading and a cytosolic iron-deficiency 
that increases transferrin receptor 1 expression [91], as well as the inhibition of tumor 
xenograft growth in vivo [92]. In a mouse model of Friedreich’s ataxia, where frataxin is 
conditionally deleted in the heart, mitochondrial ferritin expression is decreased [93]. This 
may prevent the appropriate sequestration of mitochondrial iron and play a role in the 
mitochondrial iron overload, which has characteristics of an inorganic iron crystallite [94]. 
Mitochondrial ferritin remains probably the most enigmatic protein of the ferritin family and 
deserves further investigation in terms of its roles in normal physiology and disease states. 
 
2.7 Iron Homeostasis 
2.7.1 Post-Transcriptional Regulation by Iron Regulatory Proteins  
As the human body is not able to actively excrete iron, a balance between iron uptake, 
utilization and storage must be maintained to ensure adequate amounts of iron for various 
cellular processes while preventing excess iron accumulation, which can be deleterious to 
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cells [12]. Iron homeostasis is achieved through tightly regulated transcriptional and post-
transcriptional mechanisms, which are controlled by intracellular iron concentrations [14, 
95]. 
 
The post-transcriptional control of cellular iron metabolism acts to modulate the rates of 
translation of key iron metabolism proteins [14, 23]. The iron regulatory protein (IRP)-iron 
responsive element (IRE) system is predominantly responsible for this post-transcriptional 
regulation, and allows for rapid alterations in translation of key iron metabolism proteins in 
response to intracellular iron levels [14, 23, 96]. This system relies on two key mRNA-
binding proteins, IRPs 1 and 2, which directly regulate the translation or stability of mRNAs 
possessing IREs [14, 23, 96]. Specifically, in iron depleted cells, there is increased binding of 
IRPs to IREs in the 5′- or 3′ untranslated regions (UTRs) of key mRNAs, which acts to either 
suppress translation of the mRNA (i.e., mRNAs in which the IRE is located in the 5′ UTR; 
e.g., FTH1, FTL, FPN1, etc.), or enhance stability of the mRNA against nuclease attack (i.e., 
mRNAs in which the IRE is located in the 3′-UTR; e.g., TfR1, DMT1-I, etc.) [14, 54]. 
 
However, under conditions of cellular iron loading, there is a decrease in the level of IRP-
IRE binding activity [14, 23]. In the case of IRP1 or IRP2 under conditions of high cellular 
iron, the mechanisms involved are categorically different. In the case of IRP1, this protein 
loses its IRE-binding activity by acquiring an ISC (4Fe-4S cluster) [96]. The acquisition of 
this 4Fe-4S cluster converts IRP1 into a cytosolic aconitase that cannot bind IREs. In the case 
of IRP2, iron-dependent, proteasomal degradation is the major regulatory mechanism [97]. 
This occurs by the ubiquitination and targeting of IRP2 by a subunit of the SKP1-Cullin-1-F-
box E3 ubiquitin ligase complex, namely F-box and Leucine-rich Repeat Protein 5 (FBXL5). 
FBXL5 is itself post-translationally regulated by iron and oxygen [98, 99], such that high 
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cellular iron stabilizes levels of the protein, allowing it to down-regulate IRP2 [98, 99]. 
Consequently, high iron levels promote loss of IRP2 due to proteasomal turnover [98, 99]. 
 
2.7.2 Hepcidin and Systemic Iron Homeostasis 
Over the past 15 years, a great deal of iron metabolism research has focused on hepcidin, the 
“hormone of iron metabolism”, which appears to be a keystone regulator of systemic iron 
homeostasis [100]. This 25-amino acid peptide is predominantly expressed in the liver with 
its levels being regulated by iron, inflammation, hypoxia and erythroid activity [100]. 
Hepcidin is a small (~2.8 kDa) disulfide-rich peptide that is synthesized and secreted by 
hepatocytes [101, 102], and at lower levels by the kidney and heart [24]. Once secreted into 
the plasma, the major known biological activity of this peptide is to post-translationally 
decrease the expression of FPN1 [100]. Hepcidin-dependent down-regulation of FPN1 is 
most significant in enterocytes, mononuclear phagocytes, and hepatocytes [24]. Hepcidin 
decreases Fpn1 levels via lysosomal degradation [24], which reduces the amount of iron 
released by the affected cells. Thus, hepcidin acts to decrease circulating iron levels that are 
bound to Tf. The regulation of hepcidin production and synthesis is complex, and is outside 
the scope of this review. As such, we refer readers to the following recent review on the topic 
[31]. 
 
The dysregulation of hepcidin expression is etiologically involved in many diseases of iron 
metabolism. Pathologically low hepcidin levels induces iron overload (e.g., as occurs in 
hereditary hemochromatosis types 1-3 [24]), while pathologically high hepcidin typically 
induces iron-limited anemias [24]. Importantly, the anemia of inflammation (AI) is the 
second most common anemia after iron-deficiency anemia [103]. Indeed, AI is the most 
common form of anemia in hospitalized patients, and is most common in individuals with a 
chronically activated immune system. This can result from conditions such as chronic 
 15 
infections, inflammatory diseases, kidney disease, solid organ transplantation rejection, and 
malignancies [103, 104]. 
 
In AI, the major pathophysiological event is the anemia resulting from iron-limited 
erythropoiesis that leads to decreased red blood cell production. The iron limitation is 
primarily due to an increase in circulating levels of the inflammatory cytokine, interleukin-6, 
that up-regulates expression of hepcidin, which is a type II acute-phase reactant [105, 106]. 
An increase in circulating hepcidin down-regulates FPN1 resulting in decreased iron 
absorption and recycling [103, 104]. The retention of iron within the major iron-recycling 
cells greatly diminishes the body’s effective iron supply for erythropoiesis and is a major 
cause of the restricted iron availability to erythroid precursors [104]. Indeed, it has been 
demonstrated that the pharmacological blockade of endogenous hepcidin production releases 
“trapped” iron from splenic macrophages, thereby stimulating erythropoiesis and decreasing 
the levels of anemia [107]. 
 
Interestingly, hepcidin-lowering therapeutics have the potential to play an important role in 
the treatment of AI [107]. While current strategies aim to target and down-regulate the 
transcription of the hepcidin gene, other strategies that target hepcidin transport and renal 
clearance have been proposed. 
 
The standard view of hepcidin transport is that it traverses the circulation as a free peptide. 
However, emerging evidence indicates that most hepcidin is in fact bound to plasma carrier 
proteins such as α2-macroglobulin (α2-M) and albumin [108, 109], and possibly other 
proteins such as α1-antitrypsin [110]. Indeed, α2-M was identified as the major specific 
hepcidin-binding partner in human plasma, accounting for up to 30% of protein-bound 
hepcidin [109]. This study demonstrated that α2-M in its native form possesses two high 
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affinity binding sites (Kd: 177 ± 27 nM). Intriguingly, upon the well-described activation of 
α2-M, there is exposure of further high affinity binding sites that bind hepcidin allosterically 
(Kd: ~300 nM) [109]. Notably, although there is quantitatively more hepcidin bound to 
albumin, the binding of this peptide to albumin was of a far lower affinity (Kd: ~1 mM) and 
non-saturable [109]. Moreover, the complexation of hepcidin with α2-M led to a significantly 
greater decrease in FPN1 levels in J744 cells than hepcidin alone or hepcidin in combination 
with albumin [109]. In fact, the combination of albumin and hepcidin did not enhance FPN1 
down-regulation more than with hepcidin alone [109]. 
 
A recent in vivo study showed that hepcidin bound by either α2-M or α2-M-MA had a greater 
ability to lower serum iron than an equimolar concentration of hepcidin alone [108]. 
Interestingly, the ability of hepcidin bound to α2-M or α2-M-MA to down-regulate FPN1 
levels was independent of the α2-M receptor, lipoprotein receptor-related protein 1 (LRP1) 
[108]. This suggests that endocytic uptake of the α2-M-hepcidin complex is not required for 
hepcidin to mediate its effect, which is a distinct mode of action to other α2-M peptide 
cargoes [111].  
 
Importantly, the complexation of hepcidin with α2-M led to a significant decrease in the 
appearance of hepcidin in the urine [108]. As hepcidin is a small low-Mr peptide (~2.8 kDa) 
that would be expected to be readily cleared by the kidney, the binding of this small peptide 
to a large protein such as α2-M (~725 kDa) would be expected to decrease the peptide’s renal 
clearance, as was observed [108]. Taken together, these results suggest the binding of 
hepcidin to α2-M increased its efficacy in down regulating FPN1, and that this activity may 
have occurred due to decreased renal clearance of this low Mr peptide (i.e., an increase in its 
pharmacokinetic half-life). Such results suggest that targeting the binding of hepcidin by α2-
M, (e.g., by using a competitive inhibitor) may prove to be an effective “hepcidin lowering” 
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therapeutic strategy in hepcidin-dependent pathologic hypoferremia (e.g., AI). That is, 
decreasing the binding of hepcidin to α2-M would facilitate renal excretion of this low-Mr 
peptide. 
 
3. Physiological Copper Metabolism  
Copper is an essential micronutrient that is tightly regulated in vivo to avoid deleterious 
effects, including ROS generation [112]. Copper metabolism is controlled by a well-
orchestrated system, involving absorption, transport and excretion that will be discussed in 
detail below. 
 
3.1 Copper Absorption 
Copper is largely absorbed in the small intestine, principally at the duodenum, through a 
complicated process dependent on various factors and dietary components [113, 114]. There 
is limited knowledge of the exact mechanisms by which copper crosses the cells of the 
intestinal mucosa to enter the interstitial fluid [115]. However, studies have indicated that the 
uptake of copper across the brush border can vary depending on the concentration of copper. 
At low copper concentrations the uptake was shown to be mediated by a non-energy-
dependent saturable carrier, while at higher concentrations it was shown to occur by diffusion 
[115]. Recent studies have implicated the copper transporter 1 (Ctr1, Figure 3) as being the 
primary protein responsible for the import of dietary copper across the brush border 
microvilli [116, 117]. Moreover, some studies have also indicated the role of DMT1 and 
copper transporter 2 (Ctr2) in copper uptake [118-120]. 
 
Ctr1 is a member of a larger family of high affinity copper transporters, including Ctr2, 
which has been shown to be involved in intracellular copper mobilization [121]. Notably, 
Ctr1 is an integral membrane protein with three 3 transmembrane domains forming a 
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homotrimeric pore that is highly specific for copper in the cuprous (Cu(I)) state [122]. 
Dietary copper exists as Cu(II), and therefore, must be reduced from the oxidized form to 
Cu(I). The reduction of copper is potentially mediated through metalloreductases from the 
Steap family (e.g., Steap 3 and Steap 4; Figure 3) [123], or possibly by dietary reductants 
[117]. The presumed Fe(III) reductase enzyme, duodenal cytochrome b (Dcytb), is another 
potential metalloreductase, which is also able to reduce Cu(II) [124]. The imported Cu(I) is 
then transported into the secretory compartment for loading onto Cu-dependent enzymes, or 
out from the basolateral membrane by the Cu(I)-transporting P-type ATPase, ATP7A (Figure 
3) [125]. 
 
3.2 Copper Trafficking 
Once absorbed from the diet, copper is transported into the portal circulation where it is 
delivered to the liver, a central organ for copper homeostasis, bound primarily to serum 
albumin, and to a lesser extent, transcuprein [126]. Copper is imported into cells by Ctr1 and 
rapidly binds to ubiquitously expressed intracellular copper chaperones (Figure 4) [8]. These 
chaperones transport and deliver copper directly to their specific intracellular sites or 
enzymes [127]. In the liver, copper is incorporated into the secreted protein, ceruloplasmin 
(Cp). Cp is the major copper carrying protein in human plasma, containing approximately 
70% of total plasma copper [123]. Interestingly, Cp is well known to possess ferroxidase 
activity, which catalyzes the oxidation of Fe(III) and stimulates iron release from cells [128], 
thereby facilitating its loading onto Tf for distribution [129]. Notably, mice lacking Cp have 
no apparent defect in copper absorption or distribution [130]. Therefore, other undefined 
copper-binding proteins or ligands must participate in peripheral copper distribution. 
 
Intracellular transport of copper is performed by either copper chaperones, such as Atox 1, 
Cox 17 and CCS, or bound to glutathione as a Cu(I)-glutathione complex (Figure 4) [121]. 
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These copper chaperones shuttle copper to specific compartments inside the cell [126]. For 
example, Atox1 docks with either the copper-transporting ATPase, ATP7B, in the liver, or 
ATP7A in other cells [131]. ATP7B is primarily involved in liver copper homeostasis and 
directs copper to ceruloplasmin or for biliary excretion (Figure 4). On the other hand, ATP7A 
directs copper for the biosynthesis of various secreted metalloenzymes within the trans-Golgi 
network (Figure 4) [116]. It is also involved in the basolateral efflux of copper in the intestine 
and other cells [132]. 
 
The copper chaperone, CCS, directs copper to Cu/Zn-SOD that protects cells against ROS-
induced damage (Figure 4) [133]. Cox17 delivers copper to the mitochondria for cytochrome 
c oxidase via the chaperones Cox11, Sco1, and Sco2 [134]. In contrast, the Cu(I)-glutathione 
complex serves as a vehicle for delivering copper to a family of proteins involved in 
intracellular metal detoxification, known as the metallothioneins [121]. Some studies have 
also suggested the presence of a labile intracellular copper pool, predominantly localized in 
the mitochondria and the Golgi apparatus (Figure 4) [135]. Such a pool can also be 
speculated to exist, at least transiently, in the lysosome or autophagolysosome [136] (Figure 
4) after the breakdown of copper containing proteins during the process of autophagy. This 
may be the source of “free” copper that is bound by lysosomotropic chelators that enter the 
lysosome [137, 138]. 
 
3.3 Copper Storage 
The mechanism by which eukaryotic cells store copper and mobilize this metal during times 
of deficiency is still elusive. Intriguingly, copper levels in the mitochondrial matrix are 
greater than what is thought to be necessary for the activation of copper-dependent enzymes, 
suggesting that the mitochondrion may act as a copper storage organelle [139]. Recent 
studies with yeast have demonstrated that the vacuole, analogous to the lysosome, serves in 
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both copper storage and mobilization [140]. Interestingly, Ctr2 was found to be localized to 
vacuoles and is suggested to mobilize vacuolar copper to the cytosol [140]. However, the 
mechanisms involved in the storage and mobilization of copper from these vacuoles remains 
elusive. A Ctr2-like protein has been identified in humans, but its function is currently not 
well understood [141]. 
 
3.4 Copper Homeostasis 
Copper homeostasis is maintained by complex processes involving copper absorption and 
excretion [125]. Bile is the major pathway for copper excretion (~80%) and it is vital in the 
homeostasis of liver copper levels [8]. The majority of fecal copper results from biliary 
excretion, with the rest derived from unabsorbed copper and copper in desquamated mucosal 
cells [125]. 
 
The main gene products related to copper homeostasis are the two homologous cation 
transporting P-type ATPases, ATP7A and ATP7B [142]. Patients without functional ATP7A 
develop symptoms comparable to copper deficiency [143]. This is due to the role of ATP7A 
in the transport of copper into the trans-Golgi network (TGN) for the synthesis of metallo-
enzymes and for the efflux of copper in the intestine [144]. Although ATP7B has a similar 
structure to ATP7A, it is primarily involved in liver copper homeostasis [144] and is also 
important in the brain and kidneys [145]. Mutations in ATP7B result in retention of copper 
by the liver and results in brain copper toxicity, leading to Wilson’s disease [142]. In 
addition, ATP7B is also essential in the TGN for the donation of copper to ceruloplasmin 
[144]. In the presence of excess copper, ATP7B translocates to a vesicular compartment to 
allow for biliary copper efflux [142]. Secretion of copper and copper-dependent proteins 
requires the copper chaperone, Atox1, which transfers Cu(I) to ATP7A or ATP7B [131]. This 
occurs via a series of exchanges, leading to the movement of copper across the basolateral 
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membrane of intestinal cells (ATP7A) or into the bile (ATP7B) [142]. However, despite the 
roles of ATP7A and ATP7B in copper homeostasis, little evidence suggests that their mRNA 
or protein levels are dependent on copper levels [133]. 
 
4. Essential Metals and Cancer  
Hanahan and Weinberg proposed that all cancers share essential characteristics that 
collectively dictate malignant growth [146]. These essential hallmarks include: (1) self-
sufficiency in growth signals; (2) insensitivity to inhibitory signals; (3) evasion of apoptosis; 
(4) unlimited proliferation; (5) sustained angiogenesis; and (6) tissue invasion and metastasis 
(Figure 5) [146]. Given the central importance played by iron and copper in vital cellular 
processes, such as oxidative phosphorylation, DNA synthesis, detoxification of ROS and 
angiogenesis, it is not surprising that iron and copper homeostasis is altered in neoplastic 
cells, contributing to key cancer hallmarks [16, 17, 21]. In addition, the ability of iron and 
copper to engage in electron exchange reactions (redox reactions), the very attribute that is 
responsible for their biological utility, also enables them to participate in deleterious free 
radical generating reactions [147]. The following sections will discuss how metal trafficking 
and homeostasis is perturbed in cancers, and the potential deleterious consequences of poor 
regulation of their inherent redox activity. 
 
4.1 Redox Activity of Essential Metals 
As already alluded to, iron and copper are critical for growth and proliferation due to their 
essential roles in multiple cellular processes [3, 95, 148]. Organisms are dependent on these 
transition metals due to their ability to act as cofactors within the active sites of various key 
enzymes, including RR, cytochrome c oxidase, SOD and many others [2, 3, 6, 7]. 
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In the case of iron, its catalytic utility lies in its ability to cycle between the ferrous (Fe(II)) 
and ferric (Fe(III)) states, allowing it to act as an electron donor or acceptor [2]. This feature 
results in facile redox reactions that are responsible for its biological reactivity [11]. 
Similarly, copper also exists in two oxidation states, namely the cupric (Cu(II)) and cuprous 
(Cu(I)) states. However, it is found primarily in the cupric (Cu(II)) state as it is readily 
oxidized in the presence of oxygen [147]. 
 
The Fenton reaction describes the generation of the hydroxyl radical (
•
OH) from the reaction 
of ferrous iron with hydrogen peroxide (H2O2) [149] and highlights the potential toxicity of 
free redox active Fe(II). Similarly, cuprous copper is also thought to react in an analogous 
manner with H2O2 to that of ferrous iron to generate the hydroxyl radical (
•
OH) [150]. The 
products of these reactions can induce cell death by initiating reactions with biomolecules to 
result in damage to mitochondria, lipid membranes and DNA [2, 151]. For example, 
oxidative damage to DNA can include DNA base modification or DNA strand breaks [152]. 
Moreover, excess iron can produce alkoxyl and peroxyl radicals upon reaction with 
unsaturated lipids [148] and metal-catalyzed radicals can meditate the oxidation of amino 
acids, resulting in inactivated proteins [153] Ultimately, these deleterious reactions lead to 
the impairment of multiple cellular processes and organ damage, which is evident in iron-
loading (e.g., β-thalassemia and Friedreich’s ataxia [154-156]) and copper-loading diseases 
(e.g., Wilson’s and Menkes disease [3, 142, 157]). Notably, such harmful oxidative reactions, 
especially in terms of targeting DNA, can lead to mutagenic alterations and implicates the 
role of metals in cancer development and progression [18-20]. 
 
4.2 Iron and Cancer Development 
Numerous clinical and population based studies as well as animal experiments have 
implicated iron in the development of a variety of human cancers [158-162]. Although it is 
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well established that iron can cause harmful effects through the Fenton reaction, and that 
enhanced ROS levels are observed in tumor cells [21, 147], a clear cause-and-effect 
relationship has proven difficult to establish. This is likely due to the complexity of 
carcinogenesis, involving various causative factors, including diet, lifestyle and genetics, and 
the inherent difficulties of making inferences from these types of studies [21]. 
 
Epidemiological studies and investigations in rodents have assessed the association between 
dietary iron intake and cancer risk. This research has demonstrated a link between higher iron 
intake and an increased risk of developing colorectal [161, 163] and lung cancer [160]. High 
consumption of red and processed meats is also associated with an increased risk of 
developing colorectal cancer [164]. However, it is currently unclear whether this link is 
related to the intake of excess iron, producing ROS that damage the colonic mucosa, or 
confounding issues, such as fat content or other dietary factors [164]. 
 
Studies examining the association between iron stores and cancer have demonstrated that 
patients who subsequently developed cancer had higher serum iron, total iron-binding 
capacity (TIBC) and Tf saturation at enrolment [160, 165]. Conversely, the reduction of body 
iron stores with regular blood donation was associated with a decreased risk of several 
cancers, which are thought to be promoted by iron overload, including liver, lung, colon, 
stomach, and oesophageal cancer [166]. This finding should be interpreted cautiously, as the 
cohort of blood donors is unlikely to reflect the general population. 
 
Genetically-induced iron overload, such as hereditary hemochromatosis, is linked with liver 
cirrhosis and hepatocellular carcinoma [167]. In hereditary hemochromatosis, excessive 
intestinal absorption of dietary iron results in a pathological increase in total body iron stores 
[167]. Liver cirrhosis with hepatocellular carcinoma accounts for ~20–30% of deaths in 
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untreated or poorly treated patients and represents a 20-200-fold increased risk of 
hepatocellular carcinoma in comparison to the general population [168, 169]. As further 
evidence of the role of iron in carcinogenesis, treatment of hepatitis C positive patients with 
regular phlebotomy and a low-iron diet significantly lowered the risk of hepatocellular 
carcinoma over a 5 and 10 year period [170].  
 
4.3 Iron Metabolism in Cancer 
Unraveling the complex relationship between the homeostasis of iron and other metal ions 
and tumor initiation and growth remains an active area of investigation [17, 171]. Several 
proteins that play a role in normal iron metabolism have now been implicated to contribute to 
malignancy, as their levels or activity are altered [17, 172]. The net result of these cancer-
specific alterations is often an increase in intracellular iron levels, promoting proliferation 
[17]. Nevertheless, cancer cells possess heterogeneity, and hence, different molecular 
mechanisms inducing alterations of iron-regulated proteins are likely to exist in different 
neoplastic cells. Below is a discussion of common modifications in iron regulation observed 
in cancer. 
 
4.3.1 Iron Trafficking 
Important changes in iron uptake have been identified in cancer cells, with TfR1 over-
expression observed in bladder cancer, breast cancer, lung cancer, leukemia, lymphoma and 
others [173]. Consequently, TfR1 antibodies have been used to both inhibit cancer growth 
and to deliver anti-cancer agents to neoplastic cells [173]. A correlation between increased 
TfR1 expression and tumor grade and stage have been observed in a number of studies, with 
higher expression associated with more advanced cancers [174, 175]. Some members of the 
STEAP family of metalloreductases involved in iron uptake have also been found to be over-
expressed in bladder, breast, colon, lung and prostate cancer [176]. 
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Neoplastic cells increase bioavailable iron not only by increasing iron uptake, but also by 
decreasing iron efflux [21, 177]. Hepcidin is a key regulator of systemic iron levels that binds 
to Fpn1, inducing its internalization and degradation [178]. As Fpn1 is an important 
mechanism for iron export, increased hepcidin levels lead to intracellular iron accumulation 
and reduced serum iron [179]. In fact, mutations that disrupt this pathway lead to iron 
accumulation and hereditary hemochromatosis [180]. Fpn1 was found to be down-regulated 
in breast cancer cell lines and in human breast cancer samples [181]. Moreover, decreased 
Fpn1 gene expression was significantly associated with poor prognosis of breast cancer 
patients [181]. High hepcidin levels were associated with decreased expression of both Fpn1 
and ferritin in cultured breast cancer cells [181]. Thus, neoplastic cells may possess increased 
bioavailable iron to stimulate proliferation or cancer promoting ROS. 
 
4.3.2 Iron Storage 
Iron storage is often altered in cancer cells, with ferritin expression observed to be up-
regulated in breast cancer [182], esophageal adenocarcinoma [174] and hepatocellular 
carcinoma [183]. Survival rates have been shown to be lower in primary lung cancer patients 
with high serum ferritin levels [184] and stage IIIC colorectal cancer patients with either low 
or high serum ferritin levels [185]. Additionally, high ferritin mRNA levels in tissue from 
breast cancer patients were shown to correlate with the presence of metastasis [186]. In 
contrast, a reduction in ferritin has also been demonstrated in colon cancer through the direct 
action of the proto-oncogene, c-MYC, on TfR1 and DMT expression via inducing IRP2 
expression [187, 188]. This is thought to lead to increased bioavailability of intracellular iron 
for metabolism and proliferation. In contrast, the tumor suppressor, p53, which is mutated in 
more than half of cancers, is believed to exert the opposite effect, inducing ISCU expression 
and ferritin expression, while decreasing TfR1 expression [189]. Moreover, in vitro and 
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human prostate cancer xenograft studies have demonstrated that lower ferritin levels 
promoted angiogenesis through the inhibition of high molecular weight kininogen, an 
endogenous angiogenesis inhibitor [190]. Thus, both down-regulation and up-regulation of 
ferritin may contribute to carcinogenesis. 
 
4.3.3 DNA Synthesis and the Cell Cycle 
The depletion of iron typically results in G1/S arrest or apoptosis, demonstrating that iron is 
required for cell cycle progression [172, 191, 192]. Iron is required for the catalytic activity 
of the rate-limiting step of DNA synthesis that is catalyzed by RR, making DNA synthesis 
dependent on iron [193]. In fact, RR is up-regulated in cancer cells, facilitating DNA 
replication and tumor cell division [194]. Additionally, iron can regulate the expression of 
multiple proteins and modulate signal transduction pathways involved in cellular 
proliferation, including the cyclins, cyclin-dependent kinases (cdks), p21 and p53 [192, 195, 
196]. Iron depletion has been shown to down-regulate cyclin D1, cyclin D2 and cyclin D3 
expression and inhibit phosphorylation of the retinoblastoma protein [192]. Collectively, this 
evidence illustrates that intracellular iron affects the expression of critical cell cycle 
components, and therefore, iron levels modulate cell cycle progression [192]. 
 
4.3.4 The Iron Regulated Metastasis Suppressor, NDRG1 
Apart from its effects on proteins involved in cell proliferation, iron was also found to 
modulate the expression of a metastasis suppressor gene, namely N-myc downstream 
regulated gene 1 (NDRG1) [197]. Studies utilizing iron chelators demonstrated that these 
agents markedly up-regulated NDRG1 expression in a plethora of cancer cells, with this 
effect being dependent on iron depletion [197]. In fact, supplementation with iron salts 
prevented the iron chelator-mediated increase in NDRG1 levels, further demonstrating the 
iron-mediated regulation of this molecule [197]. This study also demonstrated that the 
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increase in NDRG1 by iron chelators occurred, at least in part, via the transcription factor 
hypoxia inducible factor-1α (HIF-1α; Figure 6) [197]. Indeed, iron chelation increases levels 
of HIF-1α, which is up-regulated under hypoxic conditions and functions to directly increase 
transcription of multiple down-stream targets by binding to the hypoxia responsive element 
(HRE) in the promoter region [197]. Notably, NDRG1 has a HRE in its promoter region, 
accounting for its transcriptional up-regulation in response to HIF-1α [198]. Interestingly, 
iron chelators can also up-regulate NDRG1 independently of HIF-1α [197].  
 
A potential alternate pathway of iron-mediated regulation of NDRG1 could involve the 
eukaryotic initiation factor 3a (eIF3a; Figure 6), which was found to promote NDRG1 
expression during iron depletion in breast cancer cells [199]. In fact, silencing eIF3a 
diminished the ability of iron chelators to up-regulate NDRG1 expression [199], suggesting 
that this molecule plays an important role in the iron-mediated regulation of NDRG1.  
 
Another interesting hypothesis that has emerged very recently is the potential involvement of 
the adenylyl cyclase (AC), cAMP-dependent protein kinase (PKA) and cAMP response 
element-binding protein (CREB) signaling cascade in the iron-mediated regulation of 
NDRG1 (Figure 6) [200]. Iron depletion was found to activate AC and its down-stream 
targets PKA and CREB by modulating G-protein signaling (Figure 6) [200]. Interestingly, 
regulators of G-protein signaling (RGS) proteins, namely RGS19, were found to play a key 
role in sensing cellular iron via their iron-sulfur binding motif [200]. Hence, under conditions 
of low iron, RGS19 is stabilized, activating the AC/PKA/CREB signaling cascade (Figure 6) 
[200]. Interestingly, CREB has been reported to bind to the HRE [201] and, considering that 
NDRG1 has a HRE in its promoter [198], CREB may be directly involved in regulating 
NDRG1 expression in response to iron depletion. 
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The function of NDRG1 in cancer cells has resulted in significant interest in recent years, 
with the expression of this molecule being correlated with less aggressive cancers and 
increased patient survival for prostate [202], breast [203], colon [204], glioma [205], 
neuroblastoma [206], squamous cell carcinoma [207] and pancreatic cancers [208-210]. 
Conversely, NDRG1 expression was found to promote cancer progression and metastasis in 
hepatocellular carcinoma [211], although the mechanisms behind this paradoxical effect 
remain unclear and important to elucidate. Notably, NDRG1 interacts with multiple 
signaling pathways in cancer cells [212] and it is likely that its function can be altered by 
mutations and alterations in these pathways.  
 
Recent studies examining the down-stream targets of NDRG1 in cancer cells have discovered 
that this metastasis suppressor negatively regulates the RAS, phosphoinositide 3-kinase 
(PI3K), nuclear factor-κB (NF-κB), WNT, SRC and transforming growth factor β (TGF-β) 
pathways, all of which contribute to cancer progression and metastasis (Figure 6) [213-218]. 
In particular, NDRG1 inhibited the epithelial to mesenchymal transition (EMT; Figure 6), 
which is the first step towards metastasis [217]. This latter effect was mediated by the 
increased membrane levels of E-cadherin and β-catenin in response to NDRG1, which 
promotes formation of the adherens junctions [215, 217]. Moreover, NDRG1 also inhibited a 
number of crucial molecules involved in cell motility and migration, namely Rho-associated, 
coiled-coil containing protein kinase 1 (ROCK1) and its down-stream target phosphorylated 
myosin light chain 2 (pMLC2), leading to inhibition of stress fiber formation and cell 
locomotion [219].  
 
The ability of NDRG1 to interact with and modulate such a vast array of signaling pathways 
indicated that it may affect a crucial up-stream regulator of cell signaling. Indeed, a recent 
study has demonstrated that NDRG1 markedly inhibits activation of a number of receptor 
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tyrosine kinases, including the epidermal growth factor receptor (EGFR; Figure 6) as well as 
its family members, HER2 and HER3, all of which interact with and activate numerous 
down-stream pathways to promote cell proliferation, migration and metastasis [220]. 
 
Considering the important role of iron in regulating NDRG1 expression in cancer cells 
(Figure 6), and the myriad of oncogenic signaling pathways affected by this metastasis 
suppressor, it is clear that iron metabolism is integrally involved in cancer progression and 
metastasis. Clearly, agents that can up-regulate this molecule and its potent anti-metastatic 
activity could be important therapeutics. 
 
4.4 Copper and Cancer Development  
Excess copper is known to be a potent catalyst of ROS generation [150]. However, the role of 
copper in the growth of tumors and its profoundly altered distribution and metabolism in 
cancer was only recently demonstrated [221]. Both serum and tumor copper levels have been 
found to be significantly elevated in cancer patients [221]. Studies in breast cancer patients 
demonstrated that serum and tissue copper concentrations were increased compared to age 
matched samples, with higher values associated with advanced disease and malignancy [18].  
 
Elevated copper levels have been documented in breast, cervical, ovarian, lung, prostate, 
stomach, and leukemia [222]. Serum copper concentration has also been found to correlate 
with tumor incidence and burden, malignant progression in Hodgkin’s lymphoma, leukemia, 
sarcoma, brain, breast, cervical, liver and lung cancer [223, 224]. Interestingly, serum copper 
levels have also been observed to be linked to drug resistance in cancer [225]. Indeed, cancer 
patients that did not respond to drug treatment demonstrated 130-160% higher levels of 
copper in their serum than treatment responsive patients [225]. 
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Moreover, expression of Cp has also been reported to be elevated in a variety of cancers, 
including breast, bowel, lung and stomach cancer [226]. Indeed, Cp levels were reported to 
be increased during cancer progression and returned to relatively normal levels after tumor 
regression [226]. In fact, serum Cp has been evaluated as a diagnostic marker of cancer 
[227].  
 
Copper was also found to play an important role in the metastatic progression of breast 
cancer [228]. In fact, the metal-binding enzyme, Memo, which requires Cu(II) for its oxidase 
activity, was found to be essential for breast cancer cell motility in response to receptor 
tyrosine kinases [228]. Memo was found to affect ROS production, cell migration and in vivo 
metastasis, being correlated with poor prognostic outcomes of breast cancer patients [228]. 
 
4.5 Copper and Angiogenesis 
Copper plays an important role in angiogenesis, and thus, it is critical in cancer progression 
[229]. The dependence of cancer on angiogenesis is based on the observation that tumor cells 
are unable grow more than 1–2 mm in diameter without a supply of oxygen and nutrients 
[230]. In fact, angiogenesis is important for both tumor growth as well as metastasis [231]. 
The role of copper in angiogenesis was first discovered when it was noted that copper salts 
could stimulate the proliferation and migration of endothelial cells [232].  
 
The vascular endothelial growth factor (VEGF) family are angiogenic proteins essential in 
both vasculogenesis and hypoxia-induced angiogenesis, and recent evidence suggests that 
copper may be a required cofactor of VEGF-mediated angiogenesis [233]. In addition to 
VEGF, numerous angiogenic factors such as basic fibroblast growth factor (bFGF), tumor 
necrosis factor alpha (TNF-a), interleukin (IL) 1, IL-6, IL-8 and fibronectin has been reported 
to be activated by copper [234]. Copper has also been linked with the activation of HIF-1α, 
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by stabilizing nuclear HIF-1α under normoxic conditions, resulting in HRE-dependent 
reporter gene expression [235]. As HIF-1 α regulates the expression of the pro-angiogenic 
molecules, such as VEGF-1, this represents another mechanism by which copper regulates 
angiogenesis [236]. 
 
5. Targeting Metals in Cancer Therapy 
The high iron and copper requirements, as well as dysregulated homeostasis of these metals 
in cancer cells, has led to the discovery that compounds that can bind and sequester essential 
metal ions, namely chelators, have anti-cancer activity [237-240]. In fact, these agents belong 
to a group of chemotherapeutics known as metabolic inhibitors, which represent an important 
and broad class of anti-cancer agents. A prominent example of these drugs is the highly 
successful folate antagonists (e.g., methotrexate), which inhibit the use of the nutrient folate 
which is critical for DNA synthesis [241]. Just as folate is an essential nutrient for DNA 
synthesis, iron is also crucial for DNA synthesis and both of these nutrients are required in 
higher amounts by tumor cells, making each appropriate therapeutic targets [2, 237, 238]. 
 
For many decades, chelators have been used to treat conditions of iron or copper overload, 
such as in β-thalassemia or Wilson’s disease, respectively [242, 243]. However, it is only 
more recently that their roles in other diseases, such as neurodegeneration and cancer, have 
been considered [2, 239, 244]. By coordinating with intracellular and extracellular iron or 
copper, some of these ligands promote the excretion from the body and their subsequent 
depletion from biological systems. In contrast, other ligands can be trapped within cells in 
lysosomes [137, 138] and lead to concentration of metals (as the ligand-metal complexes) 
within the tumor, which can play a role in their anti-tumor efficacy [244]. 
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Metal chelators can be isolated from natural sources or synthesized. Siderophores are an 
example of naturally derived ligands excreted by microbes and fungi to sequester iron in an 
utilizable form [2]. Their iron chelation efficiency has led many to become lead compounds 
in the search for more effective iron chelators [245]. Currently, the siderophore, 
desferrioxamine (DFO; Figure 7A), which is produced by the bacterium, Streptomyces 
pilosus, is clinically used for the treatment of the iron overload disease, β-thalassemia major 
[65]. Moreover, DFO has also demonstrated modest anti-proliferative activity against 
neuroblastoma and leukemia cells in vitro and in clinical trials [1, 239, 246, 247]. 
 
The realization that Wilson’s disease was caused by an excess of copper [248] stimulated 
further research for copper chelating drugs. The ligand, D-penicillamine, was the first 
successful treatment for Wilson’s disease [242]. Initiation of therapy in patients with 
Wilson’s disease resulted in urinary copper excretion, leading to a large negative copper 
balance [242]. While being an effective therapy, D-penicillamine has multiple severe side 
effects, which include neurological effects and hematologic and renal toxicity [249]. In the 
search for alternatives with fewer side effects, other clinically effective anti-copper agents 
have been developed, including zinc and tetrathiomolybdate (TM) [250]. Treatment with one, 
or a combination, of these drugs leads to a reversal of copper accumulation, and in most 
patients, a clinical improvement [240]. Importantly, TM has proven particularly useful for the 
treatment of acutely ill Wilson’s disease patients with neurological manifestations [251]. Due 
to its low toxicity and rapid action, TM has been evaluated in a number of clinical trials as a 
first line therapy against acute neurological Wilson’s disease [251].  
 
The finding that angiogenesis is largely dependent on copper availability has led to successful 
trials of a number of anti-copper drugs, including D-penicillamine, trientine and TM, as anti-
angiogenic and anti-cancer agents [252, 253]. In a phase II trial of advanced kidney cancer, 
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TM was well tolerated and effectively induced copper depletion, leading to stabilization of 
the disease [254]. 
 
The development of metal chelators as anti-cancer agents has followed two broad strategies, 
namely: (1) depleting cancer cells of iron or copper, and (2) generating cytotoxic ROS within 
cancer cells by facilitating iron and copper redox cycling [17]. The following section 
introduces chelators as therapeutic agents and describes their development from agents for 
the treatment of iron and copper overload diseases to current thiosemicarbazone chelators, 
whose mechanism of action includes metal sequestration and ROS generation. 
 
6. Genesis of Chelators for Cancer Therapy 
6.1 Desferrioxamine 
The siderophore, DFO (Figure 7A) is a hexadentate chelator secreted by Streptomyces pilosus 
[255]. As the current “gold-standard” chelator for the treatment of β-thalassemia major and 
related conditions [256], this ligand has validated iron chelation as an effective therapeutic 
strategy  [257]. DFO binds ferric iron with high affinity via its hydroxamic acid groups [246] 
to form a stable 1:1 complex, which inhibits the generation of ROS, making it a suitable 
ligand for the treatment of iron overload disease [2]. 
 
Additionally, the ability of DFO to act as potential anti-cancer agent has been investigated in 
a number of in vitro and animal studies and also in clinical trials [258-260]. For example, in 
in vitro investigations, DFO was able to markedly reduce in neuroblastoma (NB) cell 
viability after a 72 h incubation [261] and the inhibition of DNA synthesis in NB cells after a 
4 h incubation [262]. Importantly, iron depletion was found to be central to the mechanism of 
action of DFO as its anti-proliferative activity was inhibited upon the addition of iron [262]. 
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A number of clinical trials investigating the potential of DFO as an anti-cancer agent have 
demonstrated mixed results. For instance, a phase II trial demonstrated a 50% reduction in 
bone marrow infiltration in 7 out of 9 NB patients, with one patient exhibiting a 48% 
decrease in tumor size after DFO treatment (150 mg/kg/5 days) [246]. In contrast, a study of 
10 patients with recurrent NB did not respond to DFO administration [247]. 
 
The poor results obtained with DFO reflect its limitations that stem from its high 
hydrophilicity, short half-life and its oral inactivity [65]. As a result, ongoing research has 
been conducted to develop far more active, selective and specific chelators for the treatment 
of iron overload, but also cancer. For further details regarding the development of chelators 
for the treatment of iron overload, readers are referred to the following review [2]. The 
sections below focus on the development of chelators for the treatment of cancer, particularly 
well-developed agents which have, or will, enter clinical trials. 
 
6.2 Thiosemicarbazones 
Tridentate thiosemicarbazones were amongst the first ligands to be comprehensively studied 
as anti-cancer agents [263-265]. These ligands show high affinity for iron, but also bind 
Cu(II), Zn(II) and other transition metals [266]. Due to the abundance of literature regarding 
thiosemicarbazones, this section will focus on research concerning the α-pyridyl 
thiosemicarbazones (Figure 7B) as anti-tumor agents. Specifically, α-pyridyl 
thiosemicarbazones bind iron utilizing the N,N,S coordination system to form octahedral iron 







 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; Figure 7C) is an α-pyridyl 
thiosemicarbazone that potently inhibits RR activity [265] and modestly suppresses cancer 
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cell growth [267, 268]. Human RR is a tetramer consisting of two non-identical homodimers, 
R1 and either R2 or p53R2 [269]. R2 is involved in DNA synthesis for housekeeping, 
whereas p53R2 is a p53-targeted gene that is transactivated by DNA damage [270]. 
Examination of structural homology revealed that both R2 and p53R2 possess an iron-
binding site important for enzymatic function [269], and thus, could potentially be inactivated 
by iron chelators [172]. In contrast to the clinically used RR inhibitor, hydroxyurea, 
Triapine
®
 was found to equally inhibit both R2 and p53R2, whereas hydroxyurea was 
relatively ineffective at inhibiting the p53R2 subunit [269]. Interestingly, Triapine
®
 did not 
remove Fe from the active site of R2 or p53R2, but instead formed redox active Fe(III) 
complexes [267]. Notably, the subsequent reduction of the Triapine
®
-Fe(III) complex 
generated ROS and quenched the tyrosyl radical of RR, leading to the inactivation of the 
enzyme and prevention of DNA synthesis and repair [267]. 
 
These above results were consistent with prior observations demonstrating the redox activity 
of the Triapine
®
-Fe complex [268]. Additionally, a subsequent investigation by Shao et al. 
(2006) demonstrated that the Triapine
®
-Fe(II) complex reduces O2 to produce ROS [267]. 
Moreover, Triapine
®
 mediated the pronounced oxidation of mitochondrial thioredoxin 2 
(Trx2) [271]. Cytosolic (Trx1) and mitochondrial (Trx2) thioredoxins are at the core of 
cellular thiol redox control and antioxidant defense, making them essential for cellular 
survival [272]. Thus, the ability of Triapine
®
 to increase Trx2 oxidation suggests the 
contributing role of redox cycling and ROS generation in anti-cancer activity [271]. 
Triapine
®
 also could increase iron release from cells, prevent Fe uptake from transferrin, and 
increase IRP-RNA-binding activity like other chelators such as DFO, demonstrating that it 
was effective at chelating iron present in intracellular iron pools [268]. 
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In vitro studies demonstrated the ability of Triapine
®
 to inhibit the growth of both HU-
sensitive and -resistant cancer cells, including L1210 leukemia and KB nasopharyngeal 
carcinoma [273, 274]. Additionally, Triapine
®
 demonstrated pronounced anti-cancer activity 
without marked toxicity in L1210 leukemia, M109 lung carcinoma and A2780 ovarian 
carcinoma xenografts in mice [265]. Triapine
®
 was also found to act in synergy with other 
chemotherapeutic agents, such as cisplatin, doxorubicin (DOX) and etoposide, to cause tumor 
regression in mouse models [265].  
 
Following the success of Triapine
®
 in cellular and animal models, this agent began evaluation 
in >20 phase I and II clinical trials against a number of cancers [275, 276] (for review see 
[21]). In a phase I trial, Triapine
®,
 administered as a single agent, decreased serum tumor 
markers associated with stable disease in 4 of 21 patients [277]. Triapine
®
 was well tolerated 
at a fortnightly dose of 120 mg/m
2
/d, whereas a dose of 160 mg/m
2
/d resulted in dose-
limiting toxicities in three of the six patients [277].  
 
Toxicity after administration of Triapine
® 
was primarily hematological, with patients 
suffering from anemia, methemoglobinemia, leucopenia and thrombocytopenia [277]. 
Moreover, patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency developed 
severe methemoglobinemia and hemolysis upon treatment [278]. This observation is likely 
due to the redox activity of the iron complexes of Triapine
®
 [268, 278, 279] and the inability 
of patients with G6PD deficiency to effectively reduce methemoglobin to hemoglobin [278]. 
Additional phase I studies examining Triapine
®
 in combination with gemcitabine 
demonstrated anti-tumor activity against a range of metastatic or advanced cancer types 
[280]. In fact, 3 out of 22 patients showed an objective partial response, while one patient 
showed evidence of tumor regression [280].  
 
 37 
Following these promising results, Triapine
®
 progressed to Phase II trials [21]. In a phase II 
study, the administration of Triapine
®
 and gemcitabine in combination resulted in an 
objective response in 3 out of 23 patients with advanced adenocarcinoma of the gall bladder 
or biliary tract [281]. Conversely, another study using Triapine
®
 as a single agent only 
reported slight activity against recurrent or metastatic head and neck squamous cell 
carcinoma [282]. A phase II trial in patients with metastatic renal cell carcinoma highlighted 
some of the deleterious side effects of Triapine
®
 upon administration at 96 mg/m
2
 during a 2 
h infusion repeated daily for a 4 day period repeated fortnightly [275]. Some of the adverse 
effects included fatigue, nausea, neutropenia, methemoglobinemia, hypoxia and hypotension 
[275]. As a result, the study was terminated early due to the limited efficacy of the treatment 
[275]. Thus, these conflicting clinical trial results have prompted others to further develop 
and refine the selectivity of potent thiosemicarbazones as anti-cancer agents. 
 
6.2.2 Di-2-Pyridylketone Thiosemicarbazones 
More recently, a more effective series of tridentate chelators, namely the di-2-pyridylketone 
thiosemicarbazone (DpT) series were synthesized (Figure 7D) [283] (Whitnall et al. 2006). 
These ligands are similar to Triapine
®
, but with the 3-aminopyridine-2-carboxaldehyde 
moiety replaced with the di-2-pyridylketone group. The generation of the DpT series was the 
result of 20 years of structure-activity relationship studies that originally began with 
analogues of the tridentate ligand, pyridoxal isonicotinoyl hydrazone (PIH) [284, 285]. These 
agents were characterized in terms of their activity [191, 192, 286], refined and eventually led 
to hybrid ligands of aroylhydrazones and thiosemicarbazones [287, 288], and then finally the 
DpT series. 
 
In initial in vitro studies, many DpT analogues demonstrated high anti-proliferative activity 
against SK-N-MC neuroepithelioma cells, MCF-7 breast cancer cells and SK-Mel-28 
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melanoma cells [283]. Of these, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone 
(Dp44mT; Figure 7D) was found to be the most potent in SK-N-MC cells and a more 
promising candidate for further evaluation [283].  
 
6.2.2.1 Dp44mT 
Dp44mT was subsequently shown to demonstrate selective and potent anti-proliferative 
activity against over 28 cancer cell lines [244], including leukemia, myeloma [289] and 
breast cancer cells [290] compared to normal peripheral blood mononuclear cells [289], 
fibroblasts [244] and mammary epithelial cells [290]. Over these 28 cancer cell-types, 
Dp44mT was shown to be on average 21 times more effective than the chemotherapeutic 
agent, DOX, and 47-fold more effective than Triapine
®
 [244]. With the emergence of multi-
drug resistant cancer cells being a significant clinical problem, it is important to note that 
Dp44mT was found to be equally or more effective in preventing the proliferation of 
etoposide-resistant breast cancer cells (MCF-7/VP) and vinblastine-resistant epidermoid 
carcinoma (KB-V1) when compared to their wild type chemo-sensitive cells [244]. 
 
Studies have demonstrated that the cellular uptake of Dp44mT occurs via a saturable 
carrier/receptor-mediated process [291]. Moreover, the abundant serum protein, human 
serum albumin, enhances the cellular uptake of Dp44mT, potentiating its anti-proliferative 
and apoptotic activity [292]. Collectively, these findings promote the development of 
strategies to improve drug delivery of this agent via the implementation of albumin-based 
drug carriers [291-293]. 
 
Studies investigating the molecular effects of Dp44mT and other α-pyridyl 
thiosemicarbazones have demonstrated their ability to induce apoptosis [283, 289] even 
though the exact signaling pathways that lead to this event were not completely understood. 
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Studies performed to examine the pathways involved in the induction of apoptosis by 
Dp44mT revealed efflux of holo-cytochrome c, increased expression of caspase-3, 8 and 9 
proteins [283] and a decrease in the mitochondrial trans-membrane potential [289] upon 
incubation with Dp44mT. Moreover, Dp44mT resulted in decreased expression of the anti-
apoptotic Bcl-2 protein, increased expression of the pro-apoptotic Bax protein [283] and 
induced G1 cell cycle arrest in leukemia and breast cancer cells [216, 283, 289]. In addition to 
the above pro-apoptotic effects, Dp44mT was also demonstrated to induce DNA double-
strand breaks, activate DNA damage and cell cycle checkpoints and inhibit DNA 
topoisomerase IIa in p53 mutant MDA-MB-231 breast cancer cells [290]. 
 
Additionally, another important target of Dp44mT is the metastasis suppressor, NDRG1 
[197, 210, 294, 295]. In fact, NDRG1 was found to be crucial for the anti-metastatic effects 
of Dp44mT in breast cancer in vivo, as knocking-down NDRG1 markedly blocked Dp44mT-
induced metastasis suppression [295]. Considering the multiple down-stream effects of 
NDRG1 (see Section 4.3.4 above), it is notable that Dp44mT was found to have similar 
down-stream effects, being able to inhibit TGF-β, ROCK/pMLC2, SRC, PI3K, RAS and 
WNT signaling pathways [212, 214, 216-219, 295]. Moreover, Dp44mT also inhibited the 
EMT, restoring E-cadherin and β-catenin levels at the cell membrane and promoting the 
formation of adherens junctions [215, 217]. 
 
Due to the ability of Dp44mT to up-regulate NDRG1, this agent also was able to inhibit the 
levels and activation of the crucial ErbB family of receptor tyrosine kinases, namely EGFR, 
HER2 and HER3 both in vitro and in vivo in pancreatic cancer cells [220]. Collectively, the 
ability of the DpT class of thiosemicarbazone chelators to up-regulate NDRG1 expression 
leads to multiple down-stream effects which result in general inhibition of cancer progression 
and metastasis.  
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Several studies have examined the detailed molecular and cellular mechanisms responsible 
for the anti-tumor efficacy of Dp44mT. Yuan et al. (2004) suggested that ROS partially 
mediated the cytotoxic effects of the DpT ligands after observing that the Dp44mT-iron 
complex was redox-active [283]. Furthermore, the redox potentials of the DpT-iron 
complexes were within the range of cellular reductants and fully reversible, a feature 
attributed to the thioamide moiety [296]. This assertion was confirmed in later studies where 
the cytotoxic activity of Dp44mT was shown to be dependent on the generation of cytotoxic 
ROS [138].  
 
In addition to iron complexation as a source of ROS generation, the copper complexes of 
Dp44mT have been shown to be potently redox-active and able to induce hydroxyl radical 
formation [138]. Notably, the copper complex of Dp44mT exhibited greater in vitro efficacy 
against SK-N-MC and MCF-7 tumor cells than either the ligand alone or the iron complex 
[138]. This suggests that copper binding and the redox activity of the Cu-Dp44mT complex 
may be a key component of the anti-cancer efficacy of Dp44mT. Moreover, the 
lysosomotropic properties of Dp44mT lead to it becoming charged at the pH of the lysosome, 
resulting in its accumulation within this organelle [138]. Once inside the lysosome, Dp44mT 
forms redox-active complexes with chelatable copper that then induces oxidative stress, 
resulting in lysosomal membrane permeabilization (LMP) [138]. This subsequently leads to 
release of cathepsins from the lysosomes into the cytosol, and through downstream effector 
activation of the mitochondrial apoptotic machinery [138].  
 
Interestingly, the increase in thiosemicarbazone toxicity towards cells over-expressing P-
glycoprotein (Pgp), a drug efflux pump that confers drug resistance, was also found to be 
linked to lysosomal targeting [137, 297]. In many cancers, Pgp expression has been shown to 
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markedly reduce the toxicity of classical chemotherapeutic treatments (e.g., DOX), due to its 
ability to efflux these compounds from the cell [298]. More recently, it has also been shown 
that Pgp is present on lysosomes and can lead to the sequestration of drugs such as DOX 
within lysosomal “safe houses” (Figure 8A) [299]. Hence, together with active Pgp-mediated 
efflux from cells, the safe storage intracellularly of DOX in lysosomes by lysosomal Pgp 
pumps can result in resistance to this cytotoxic agent (Figure 8A) [299, 300]. 
 
Notably, Dp44mT due to its very unique properties can overcome multidrug resistance via 
“hijacking” lysosomal Pgp to increase its accumulation in this organelle, leading to enhanced 
LMP (Figure 8B) [137]. The ability of Dp44mT to overcome multidrug resistance has been 
attributed to a number of important characteristics of this agent, namely: (1) the agent must 
act as a Pgp substrate; (2) the agent must become charged at acidic lysosomal pH, leading to 
lysosomal accumulation; and (3) the drug must cause marked redox stress within the acidic 
lysosome, leading to LMP [137]. Thus, while DOX which fulfills criteria (1) and (2), it does 
not satisfy criterion (3), as it does not possess the potent redox activity of the Dp44mT-
copper complex which markedly induces LMP [137]. Hence, thiosemicarbazones, such as 
Dp44mT, may prove valuable agents for patients with drug resistant tumors [301]. 
 
In addition to the very promising properties above, Dp44mT markedly inhibited the growth 
of human lung carcinoma, neuroepithelioma and melanoma tumor xenografts in nude mice 
[244]. Following 7 weeks of treatment with Dp44mT (0.4 mg/kg per day) via intravenous 
administration, SK-Mel-28 melanoma xenografts were 92% smaller than control tumors 
treated with vehicle [244]. These studies also unfortunately revealed that Dp44mT induced 
cardiac fibrosis in a dose-dependent manner at high non-optimal doses >0.75 mg/kg/d [244]. 
Superficially, this dose-limiting toxicity could be said to appear somewhat similar to that 
observed with the clinically used chemotherapeutic agent, DOX [302]. However, it is notable 
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that the cardiotoxic effects of DOX and Dp44mT are different anatomically and 
histologically, suggesting a different cytotoxic mechanism for each of these agents 
(Richardson, D.R. unpublished data). 
 
6.2.2.1 DpC 
In an effort to develop more highly potent and selective DpT analogues, the structure of 
Dp44mT was modified to generate a new series of second generation DpT analogues, with 
di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC; Figure 7D) being the 
current lead compound [294, 303]. Importantly, DpC has shown to be significantly more 
effective and better tolerated than Dp44mT both in vitro and in vivo [294, 303]. Moreover, 
unlike Dp44mT, DpC has demonstrated in vivo anti-tumor activity by both the intravenous 
and oral routes [294, 303]. In fact, this is a significant advantage of DpC, as Dp44mT is toxic 
when given orally [304]. DpC has also demonstrated marked activity at the molecular level, 
with the agent increasing the expression of the potent metastasis suppressor, NDRG1, and the 
cyclin-dependent kinase inhibitor, p21
CIP1/WAF1
, while decreasing cyclin D1 levels [294]. 
Furthermore, DpC demonstrated greater activity than the standard chemotherapeutic 
treatment against pancreatic cancer, namely gemcitabine, with studies showing complete 
inhibition of pancreatic tumor xenograft growth, and unlike Dp44mT, demonstrated no 
evidence of cardiac fibrosis [220, 294]. 
 
Importantly, similar to Dp44mT, DpC also has been shown to overcome resistance to 
standard chemotherapy by “hijacking” lysosomal Pgp to increase targeting of lysosomes and 
inducing LMP (Figure 8B) [137, 297]. Moreover, tumor microenvironment stress induced by 
extremely low or high glucose concentrations rapidly increased Pgp expression in lysosomes, 
leading to enhanced cytotoxicity and LMP by Dp44mT and DpC [297]. Hence, both Dp44mT 
and DpC display great potential to target multidrug resistant tumors where a stressful micro-
 43 
environment exists that amplifies their anti-tumor activity and ability to overcome resistance 
[297]. 
 
While the anti-tumor activity of both Dp44mT and DpC is related to their activity in terms of 
binding metals and inducing ROS and LMP [297, 303], a potential toxic side effect is the 
ability to induce oxidation of oxyhemoglobin to methemoglobin, which cannot transport 
oxygen [279]. This problem has been reported for Triapine
®
 previously [275, 305, 306] and is 
potentially due to its redox activity [268]. Similarly to Triapine
®
, Dp44mT induced oxidation 
of oxyhemoglobin in vitro using intact erythrocytes and erythrocyte lysates, and also in vivo 
in mice [279]. This marked activity was due to the formation of a redox active iron complex, 
but not the copper complex. The results from these studies supported a hypothesis that 
oxidation of oxyhemoglobin by thiosemicarbazone-iron complexes follow an outer-sphere 
mechanism occurring over the exposed heme edge, as reported for other iron(III) complexes 
[307]. Further studies suggested that the terminal –NH2 groups of both the DpT ligand and 
Triapine
®
 may H-bond to the propionate groups of the heme moiety facilitating electron 
transfer [308]. 
 
In contrast to both Triapine
®
 and Dp44mT, DpC demonstrated markedly lower activity at 
oxidizing oxyhemoglobin in intact erythrocytes and erythrocyte lysates, and did not increase 
the formation of oxyhemoglobin in vivo using mice [279]. In this case, the reduced oxidation 
may relate to an steric inability of DpC to approach the exposed heme edge due to 
incorporation of the bulky cyclohexyl substituent, inhibiting H-bonding to the propionate 
moieties of the heme prosthetic group [308]. Clearly, the markedly reduced oxidation of 
oxyhemoglobin by DpC in mice is a critical advantage over both Triapine
®




Another important property that leads to the greater anti-tumor efficacy of DpC relative to 
Dp44mT has been shown by recent pharmacokinetic studies in rats [309]. In contrast to DpC, 
Dp44mT undergoes pronounced demethylation in vivo, which may be related to its quicker 
elimination (t1/2 = 1.7 h for Dp44mT vs. 10.7 h for DpC) and lower exposure [309]. 
Significantly, the in vivo metabolism of Dp44mT resulted in decreased anti-cancer activity of 
the agent. Hence, DpC possesses highly favorable pharmacokinetics that demonstrate a 
marked improvement relative to Dp44mT. Considering the many favorable pharmacological 
characteristics of DpC, this agent has been commercialized and will undergo clinical trials in 
humans in 2016 [301]. 
 
6.2.3 2-Benzoylpyridine Thiosemicarbazones 
The 2-benzoylpyridine thiosemicarbazone (BpT) series were developed through modification 
of the DpT series via the substitution of the non-coordinating pyridyl group with a phenyl 
ring (Figure 7E) [310]. The rationale for this alteration lay in enhancing the lipophilicity of 
the ligand, while simultaneously lowering the Fe(II)/Fe(III) one electron redox potential by 
replacing the pyridyl group with phenyl moiety [310]. 
 
In vitro studies using SK-N-MC neuroepithelioma cells demonstrated the potent and selective 
anti-proliferative activity of the BpT series [310]. The most potent BpT compounds exhibited 
greater anti-proliferative activity than DFO, Triapine
®
 and most analogs of the DpT class, 
with the exception of Dp44mT [310]. The most active BpT analog was 2-benzoylpyridine 4-
ethyl-3-thiosemicarbazone (Bp4eT; Figure 7E), which demonstrated comparable anti-
proliferative activity to Dp44mT [310], despite its higher cellular uptake [291, 311]. These 
ligands, in addition to demonstrating selectivity against neoplastic cells [310], were also 
found to possess higher anti-proliferative activity against vinblastine-resistant KB-V1 
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epidermoid cells relative to non-resistant KB3-1 cells, suggesting their ability to overcome 
drug resistance [304]. 
 
Examination of the ability of the BpT analogs to mobilize iron revealed their ability to 
remove iron from pre-labeled cells and prevent iron uptake from Tf, but they were less 
effective than their DpT counterparts [312]. Cell-free and in vitro studies examining the 
redox activity of these chelators demonstrated that the iron complexes of the BpT series 
generally exhibited greater redox activity in comparison to the complexes of DpT-iron 
complexed counterparts [310, 312]. It was proposed that this latter property contributed to the 
generally greater observed anti-proliferative activity of the BpT series compared to their DpT 
counterparts [310]. Further investigation with the lead compound, Bp4eT, revealed that, 
similarly to Dp44mT, Bp4eT also inhibited RR activity [304]. Yu et al. (2011) suggested that 
the ability of the BpT analogs to inhibit RR could occur via iron deprivation and the 
modulation of cellular thiol-related anti-oxidant systems [313]. 
 
Due to the poor aqueous solubility of Bp4eT, it could not be administered at doses 
appropriate for potent anti-tumor efficacy during in vivo studies [304]. In contrast, the BpT 
counterpart, 2-benzoylpyridine 4,4-dimethyl-3-thiosemicarbazone (Bp44mT; Figure 7E) was 
successful at inhibiting DMS-53 tumor growth via both the oral and intravenous routes [304]. 
Toxicological examination of Bp44mT-treated mice revealed mild anemia, decreased hepatic 
and splenic iron levels, decreased serum albumin levels and an increase in serum liver 
enzymes [304]. Notably, several of the toxicological changes observed to be reversed upon 
cessation of Bp44mT treatment. Additionally, in contrast to Dp44mT, administration of 
Bp44mT did not lead to significant weight loss or cardiac fibrosis [304]. 
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The in vivo investigations of Bp44mT against tumor xenografts revealed that tumor iron 
levels were not significantly changed following Bp44mT administration [244, 304], in line 
with previous findings for Dp44mT [244, 304]. Upon examination of the tumor xenografts, a 
significant decrease in TfR1 expression and an increase in ferritin heavy chain expression 
were observed, indicating augmentation of tumor iron pools by Bp44mT [304]. In contrast, 
tumor xenograft copper and zinc levels remained unchanged [304]. Collectively, this in vivo 
study demonstrated the potent anti-tumor efficacy of Bp44mT upon oral administration, a 
property important for improving patient convenience and compliance. 
 
6.2.4 Bis(thiosemicarbazones) 
A related class of agents that have anti-tumor activity are the bis(thiosemicarbazones) [314, 
315]. The anti-cancer activity of glyoxal-bis(thiosemicarbazones) were first investigated in a 
1958 study against Sarcoma 180-bearing Swiss mice [315]. In this study, the highest anti-
cancer activity was evident in compounds administered orally at doses ranging from 50–150 
mg/kg for a period of 7 days [315]. Moreover, treatment with glyoxal-bis(N4-methyl-3-
thiosemicarbazone) (GTSM, Figure 9) led to a 45% reduction in tumor weight, when 
compared with untreated controls [316]. Intriguingly, bis(thiosemicarbazones) derived from 
2,3-butanedione, including ATSM (Figure 9), were inactive in this model [316]. 
 
Investigations regarding the bis(thiosemicarbazone) derivative, kethoxal-
bis(thiosemicarbazone) (KTS, Figure 9), demonstrated that this agent possessed excellent 
anti-tumor activity against rodent tumor xenografts [317]. The mechanism of action of KTS 
was unknown, but its anti-tumor efficacy was observed to be dependent on nutritional intake 
and, in particular, dietary Cu(II) intake [318]. The importance of Cu(II) in the activity of 
bis(thiosemicarbazones) was subsequently underlined by studies which combined Cu(II) and 
KTS to form Cu(KTS) (Figure 9) [319]. This complex resulted in inhibition of DNA 
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synthesis in sarcoma 180 ascites cells [319], and importantly, possessed anti-tumor activity 
against Walker 256 carcinoma in rats [320].  
 
Notably, complexation of bis(thiosemicarbazones) with Cu(II) involves the double 
deprotonation of the ligand to yield a neutral bis(thiosemicarbazonato)Cu(II) complex 
(Figure 9). This resulting complex is highly lipophilic and able to rapidly traverse cell 
membranes [321]. Once inside cells, complexes such as Cu(II)(KTS) are believed to 
dissociate in a process involving reduction to release Cu(I). This process is possibly assisted 
by intracellular thiols [322]. Upon dissociation, Cu(I) is then distributed within the cell [321]. 
Evaluation of a series of substituted bis(thiosemicarbazonato)Cu(II) complexes demonstrated 
a correlation existed between their cytotoxicity and their reactivity towards thiol groups, 
suggesting that their activity was dependent on the intracellular release of Cu following the 
reduction of the complex [322].  
 
Intriguingly, subtle changes to the ligand backbone can dramatically alter the biological 
properties of bis(thiosemicarbazones) [323]. This particular property has been exploited in 
investigations evaluating their suitability as radiopharmaceuticals for the imaging of hypoxic 
tissue [324, 325]. In contrast to Cu(KTS), where Cu is released intracellularly regardless of 
oxygen levels, the Cu(ATSM) complex enters cells and only releases Cu under hypoxic 
conditions [321, 324, 326]. This results from the different reduction potentials of Cu(ATSM) 
and Cu(KTS), and could account for the lack of biological activity of Cu(ATSM) in the 
above-described in vivo studies against Sarcoma 180 [315]. 
 
It is currently unknown as to how the Cu is subsequently metabolized once released from the 
ligand. On binding to intracellular proteins, Cu may be sequestered to particular subcellular 
compartments with a range of downstream effects. Recently, it was reported that Cu(GTSM), 
 48 
but not Cu(ATSM), activated PI3K-dependent signaling, leading to downstream regulation of 
Alzheimer’s amyloid peptide accumulation [327]. Subsequent in vivo investigations 
demonstrated that Cu(GTSM) led to cognitive improvement in an Alzheimer’s disease mouse 
model, which was associated with altered metabolism of amyloid processing and microtubule 
tau protein phosphorylation [328]. In contrast, Cu(ATSM) did not mediate this effect in the 
same Alzheimer’s disease model [327].  
 
An investigation of the anti-cancer activity of Cu(GTSM) against human NB cells 
demonstrated cell cycle arrest as assessed by fluorescent activated cell sorting (FACS) 
analysis [329]. Protein array analysis revealed the ability of Cu(GTSM) to mediate cell cycle 
arrest via the potent reduction of cyclin D1 expression and an increase in Kip2 expression 
[329]. 
 
More recently, the activity of both Cu(GTSM) and Cu(ATSM) was assessed in the transgenic 
adenocarcinoma of mouse prostate (TRAMP) model [314]. In this investigation, Cu(GTSM) 
was shown to reduce prostate cancer burden and severity, while Cu(ATSM) was ineffective 
[314]. Interestingly, similarly to observations using Dp44mT and DpC [137, 138, 297, 330], 
studies have demonstrated that GTSM could mediate the induction of LMP [331]. Both 
copper chelation and ROS generation were shown to be crucial for this effect, and 
consequently, its anti-cancer activity [331]. Collectively, these studies demonstrate the 
potential of bis(thiosemicarbazones) as potent anti-tumor agents and again the role of metals 







A very fine balance is required for the maintenance of the precise levels of iron and copper 
that are necessary for the physiological functioning of cells. Alterations in metal homeostasis 
can have deleterious effects, resulting in cancer development and progression. Novel 
chemotherapeutic strategies have been developed to exploit the dual nature of metal ions in 
cancer cells. 
 
Notably, agents that can bind iron and copper, such as the DpT series of metal chelators, have 
shown great promise as potent and selective anti-cancer agents. Importantly, apart from their 
ability to bind metal ions and form cytotoxic redox active complexes, these agents also affect 
an array of molecules that play crucial roles in cancer cell proliferation, migration and 
invasion. As a result of this polypharmacology, the DpT compounds are able to markedly 
inhibit both tumor growth, as well as metastasis, further contributing to their potent and 
selective anti-cancer effects.  
 
Another important facet of the DpT compounds is their ability to over-come resistance to 
currently used chemotherapeutics. Notably, one of these agents, namely DpC, is entering 
clinical trials in 2016, demonstrating the potential of exploiting redox cycling metal ions as 
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Figure 1. The cellular uptake of iron by enterocytes. Dietary iron, including heme and 
inorganic iron, is absorbed from the apical membrane of duodenal enterocytes. Ferric iron is 
reduced to its ferrous form by duodenal cytochrome b (Dcytb), allowing for its transport 
across the apical border by the divalent metal transporter 1 (DMT1). Heme iron is potentially 
absorbed via the heme carrier protein 1 (HCP1 or PCFT) into enterocytes, where it is 
subsequently degraded by heme oxygenase (HO-1) to release iron in the ferrous state. Iron 
(likely as iron(II)) is then effluxed at the basolateral membrane through the iron efflux pump, 
ferroportin1 (Fpn1), whereby hephaestin and ceruloplasmin act to oxidize iron(II) to iron(III). 
 
Figure 2. Cellular iron homeostasis. Iron circulates throughout the body bound to transferrin 
(Tf). This Tf-iron(III) complex then binds to transferrin receptor 1 (TfR1) present on the 
plasma membrane of cells and is subsequently endocytosed by receptor-mediated 
endocytosis. The acidic environment of the endosome results in the disassociation of iron(III) 
from Tf. This released iron(III) is then reduced by the ferrireductase enzyme (STEAP3) to 
iron(II) and is then transported out of the endosome by divalent metal transporter 1 (DMT1). 
Upon entering the cytosol, iron joins the labile iron pool (LIP). Iron can then be utilized for 
storage in ferritin, for protein synthesis, for heme or Fe sulfur-cluster synthesis in the 
mitochondria, and/or for export via ferroportin 1 (Fpn1). 
 
Figure 3. Copper absorption and distribution. Dietary copper (Cu(II)) is absorbed by brush 
border microvilli at the apical surface. An unidentified brush border metalloreductase reduces 
Cu(II) to Cu(I), allowing for its transport across the membrane by the high-affinity Cu(I) 
transporter Ctr1. Cu(I) can then be utilized for incorporation into Cu-dependent enzymes or 




Figure 4. Copper uptake, trafficking and excretion. Circulating Cu(I) is imported at the 
plasma membrane of hepatocytes by Ctr1 and directed to either Cu/Zn SOD1 by the 
chaperone, CCS. On the other hand, copper can be excreted into the bile duct by ATP7B after 
the donation of Cu to this protein by Atox1. Copper may also form complexes with 
unidentified ligands (L) or enter a labile intracellular copper pool, predominantly localized in 
the mitochondria, Golgi apparatus and possibly the lysosome or autophagolysosome [136]. 
 
Figure 5. The six essential characteristics of cancer include the ability to sustain proliferative 
signaling, an insensitivity to inhibitory growth signals, resisting cell death, unlimited 
proliferation, sustained angiogenesis and the invasion of tissue and metastasis. 
 
Figure 6. The expression of the metastasis suppressor protein, N-myc downstream-regulated 
gene 1 (NDRG1), can be regulated by iron levels via the hypoxia inducible factor-1α (HIF-
1α), eukaryotic initiation factor 3a (eIF3a) and/or the cAMP response element-binding 
protein (CREB) signaling cascade. Notably, this metastasis suppressor negatively regulates 
the RAS, phosphoinositide 3-kinase (PI3K), nuclear factor-κB (NF-κB), transforming growth 
factor β (TGF-β), WNT and the Rho-associated, coiled-coil containing protein kinase 1 
(ROCK1)/phosphorylated myosin light chain 2 (pMLC2) pathways, which is potentially 
mediated by its effects on inhibiting the epidermal growth factor receptor (EGFR), leading to 
the subsequent inhibition of the epithelial to mesenchymal transition (EMT), cell 
proliferation, migration and motility. 
 
Figure 7. Line drawings of the chemical structures of: (A) desferrioxamine (DFO); (B) α-
pyridyl thiosemicarbazone; (C) Triapine
®
; (D) di-2-pyridylketone thiosemicarbazone (DpT); 
and (E) 2-benzoylpyridine thiosemicarbazone (BpT). 
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Figure 8. (A) During endocytosis, the invagination of the plasma membrane results in the 
topology of Pgp to be inverted in the early endosomes formed. Upon the maturation of 
endosomes into lysosomes, the functional Pgp present in lysosomal membranes leads to the 
accumulation of Pgp substrates, such as doxorubicin, in the lysosomal “safe house”. Due to 
the acidic pH of the lysosome, doxorubicin becomes protonated and trapped in this organelle 
without leading to lysosomal membrane permeabilization (LMP). This results in decreased 
levels of free doxorubicin to interact with its intracellular target (e.g., the nucleus) and 
confers drug resistance. (B) The Pgp substrates, Dp44mT or DpC, are also pumped into the 
lysosome where they become protonated and trapped. However, in contrast to doxorubicin, 
Dp44mT or DpC form redox active iron and copper complexes in this organelle, leading to 
pronounced ROS generation and marked LMP. This leads to the initiation of apoptosis, and 
collectively, the ability to overcome drug resistance due to death of the cancer cell. 
 
Figure 9. Line drawings of the chemical structures of 1,2-bis(thiosemicarbazones), including 
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